Form 8-K - Current report:
SEC Accession No. 0001104659-25-044372
Filing Date
2025-05-05
Accepted
2025-05-05 09:25:23
Documents
13
Period of Report
2025-05-05
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2513960d1_8k.htm   iXBRL 8-K 27683
  Complete submission text file 0001104659-25-044372.txt   199810

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nvax-20250505.xsd EX-101.SCH 3011
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nvax-20250505_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nvax-20250505_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2513960d1_8k_htm.xml XML 3558
Mailing Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878
Business Address 700 QUINCE ORCHARD ROAD GAITHERSBURG MD 20878 240-268-2000
NOVAVAX INC (Filer) CIK: 0001000694 (see all company filings)

EIN.: 222816046 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-26770 | Film No.: 25911264
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)